VanEck Pharmaceutical ETF PPH
121.03 USD +2.43 (+2.05%)
Nov 4, 2026, 9:52 AM EST
120.60 Day range 121.50
92.75 52-week range 121.03
- YTD
- +17.31%
- 1 year
- +30.49%
- Market cap
- 1.13B
- EPS (ttm)
- 4.37
- P/E ratio
- 27.60
- YTD return
- +17.31%
- 1-year return
- +30.49%
- Volume
- 241.94K
- Avg volume
- 313.65K
- Open
- 121.50
- Previous close
- 118.60
- Day's range
- 120.60 – 121.50
- 52-week range
- 92.75 – 121.03
2Y +30.18 (+33.23%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 112.64
- 200-day average
- 107.98
About VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
News
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF 
PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade) 
Two Years to Build or Pay 200% — Which US Pharma Stocks Win? 
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery 
What's Going On With Merck Stock Tuesday? 
Biotech ETF With A Twist: Defiance To Donate Initial Advisory Profits To Autism Causes 
Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery 
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' 
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus 
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk
Your note
Sign in to keep a note on PPH — it syncs with the Stock Master app.